Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

JOURNAL ARTICLE published 1 February 2021 in Nature Communications

Research funded by Fundación Alfonso Martín Escudero (N/A) | U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA205426,R35 CA232097)

Authors: Cristina Valero | Mark Lee | Douglas Hoen | Kate Weiss | Daniel W. Kelly | Prasad S. Adusumilli | Paul K. Paik | George Plitas | Marc Ladanyi | Michael A. Postow | Charlotte E. Ariyan | Alexander N. Shoushtari | Vinod P. Balachandran | A. Ari Hakimi | Aimee M. Crago | Kara C. Long Roche | J. Joshua Smith | Ian Ganly | Richard J. Wong | Snehal G. Patel | Jatin P. Shah | Nancy Y. Lee | Nadeem Riaz | Jingming Wang | Ahmet Zehir | Michael F. Berger | Timothy A. Chan | Venkatraman E. Seshan | Luc G. T. Morris